Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. - Test2 - elhamkhani - TriplyDB

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

http://www.wikidata.org/entity/Q37381606

about

Brainstem Glioma in Adults IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives The role of piRNA and its potential clinical implications in cancer In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation.Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies Deregulated proliferation and differentiation in brain tumors.The Warburg effect: a balance of flux analysis IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis.Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes Identification of endometrial cancer methylation features using combined methylation analysis methods.Isocitrate dehydrogenase mutations in gliomas Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.IGFBP2 expression predicts IDH-mutant glioma patient survival.Metabolic enzymes: key modulators of functionality in cancer stem-like cells.Harnessing the potential of epigenetic therapy to target solid tumors.Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.Therapeutic targeting of tumor suppressor genes Genomic discoveries in adult astrocytoma Epigenetic therapy for solid tumors: from bench science to clinical trials.Context-dependent actions of Polycomb repressors in cancer.Molecular profiling of gliomas: potential therapeutic implications.Driver mutations of cancer epigenomes.Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression.IDH mutations in cancer and progress toward development of targeted therapeutics.Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.Targeting the cancer epigenome for therapy.Investigational new drugs for brain cancer.Epigenetic Determinants of Cancer.Further understanding of the pathology of glioma: implications for the clinic.

P2860

Q26739232-E3127D05-5BC4-404E-ADA1-97D8D2D51136 Q28066926-2D628B2D-E543-49AF-9FE9-157A8A1247DF Q28083603-C2EE4983-6D6F-42B2-BA1D-9E85752E401A Q33638225-D321F09F-C9E1-423D-92C4-D810DA98A3A2 Q33835913-D02879D0-5849-408B-9469-84BDB5F17DEA Q33920767-41C4E584-F879-4953-9957-542B1DB6E2D6 Q34374136-10B56BC6-F686-40BA-A9D1-0A1C0600952E Q34501052-0B83DC41-8164-451E-A6F7-5497B8D3B7EA Q34518462-52726EC8-359E-45A7-9011-CD9AF3669450 Q34552042-E43A9C66-4EC0-43F5-AE03-2AA0B7E4CC5F Q34661033-337D9A5E-80FD-44F7-ABEC-4262CE785FEB Q34859989-667AFBBA-F37F-4BF2-94BB-B42A6E9FEEFF Q35865839-4EFF785B-55B4-4752-82C0-C6829FCC8EDC Q36008323-F3EE0D22-03B4-42D0-B0CA-9E6FB401A32E Q36111611-991EBC2E-C382-40DF-8407-19A1B5AE6416 Q36302529-164A470A-9333-4CEB-BC93-CDEC9EAAA279 Q36367409-E75AE472-1E12-4050-9983-2B6FE85605C7 Q36385589-43EB2CE1-7FCF-4BE3-92DB-91DC7D42FD3C Q36759382-077A99B2-0642-498F-8A8D-EC2C09B8D83A Q36805635-54D1BB97-42E0-404A-8F46-50C5316466BE Q37592666-DEDDD6A6-58F2-4F7E-84C2-ECD78FA52E2B Q37697396-31F8D5AB-F373-4867-9E84-C4C15B189329 Q37702193-342C171A-FE57-4F7B-B459-DC40BC0AB42F Q37706766-78E5EBC7-3008-4F83-AD3A-A556E9C238CE Q38175087-36098F72-E576-4D6E-AB96-A422E5A94C55 Q38240032-857FB930-9602-4EC1-9D34-D4A1E2F3B727 Q38306663-384C8B55-B6A9-4C20-9C77-68835304E186 Q38330237-2DBE60B6-BD81-4E09-A90B-814EE792E105 Q38459836-A1FBE309-E7DA-4917-9AC3-4757DCE11FA3 Q38518851-EB29E99E-2D3A-49F5-82FE-F7057883B29B Q38539422-82E45002-7D86-4238-BEFB-57738E839780 Q38639828-33755563-F456-42F6-8C61-4D627D46EB50 Q38663615-FA09C6D6-31AD-42D0-81BF-67A0AD5610DC Q38732546-A1FC4E36-BB30-4223-98FC-04D9FA073CC9 Q38785528-A0697ABB-63FB-4ECD-9CCA-09BA4A4C285B Q38813611-064CCE19-64C4-4475-B278-49B3800EE3F7 Q38821103-7B2A300F-9AFF-495A-847E-722B1721F7B3 Q38832510-52892EF9-47AA-4A9E-B25A-A0ADBACF2AC0 Q38837858-37032DD7-3C09-486D-83C4-5A7DA632DDA5 Q38844945-D78A1D74-2FF0-4242-AEE3-0B242711140E

P2860

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

http://www.wikidata.org/entity/Q37381606

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficient induction of differe ...... the DNMT Inhibitor Decitabine.

@en

Efficient induction of differe ...... the DNMT Inhibitor Decitabine.

@nl

type

label

Efficient induction of differe ...... the DNMT Inhibitor Decitabine.

@en

Efficient induction of differe ...... the DNMT Inhibitor Decitabine.

@nl

prefLabel

Efficient induction of differe ...... the DNMT Inhibitor Decitabine.

@en

Efficient induction of differe ...... the DNMT Inhibitor Decitabine.

@nl

P1433

Q37381606-19BE4782-41A9-455A-872F-55B4C333730B

P1476

Q37381606-C97FA202-8974-4CED-9632-FEC44BE5D50F

P2093

Q37381606-0B8B296B-B0E4-424C-A7DF-3C833DB3967F

Q37381606-0F683CD6-7B13-485B-A898-0C748189B205

Q37381606-19883EBF-48BF-40C3-A715-D4B644F05027

Q37381606-1E0871C7-3135-4486-8AEE-2721907969D8

Q37381606-5928CD15-AEF2-4683-AB57-6D43A2E9CBB6

Q37381606-A271671E-CCE9-464C-AD11-2861C19F8E40

Q37381606-DF7F16F5-468D-4672-80F6-66B097120A3D

P2860

Q37381606-0E8BA505-37BB-4DA3-A50C-91E4B400DBF5

Q37381606-223B9D99-40DB-43C0-9F2A-5D248495B101

Q37381606-3AAE2B04-CC18-4828-89AB-310B1F8A9C7A

Q37381606-41B33927-8584-400F-9A0B-1FE572C03593

Q37381606-52860976-EDA2-47F8-8D39-1EE6FC6BB334

Q37381606-5DF46EA5-AB4B-41AE-8A59-CF0ED3A8CB64

Q37381606-65A8294E-0B20-4DF2-9EEC-C61774008141

Q37381606-7963C600-446A-4098-93F6-97E11AA759AC

Q37381606-7ABFCB02-28B0-4766-8123-103909C14868

Q37381606-81FF8143-FB34-4087-9345-224E66CAF852

P304

Q37381606-53489633-6B1F-470A-A1B8-C6886DCEBF1D

P31

Q37381606-9E9B9AAE-8710-483C-9696-D7DB1A984B7E

P356

Q37381606-5D87BFE7-FF24-4793-B17A-4AC7CF6AF922

P407

Q37381606-CFFB7A82-8212-492B-930A-5316581843FA

P433

Q37381606-FFAC50A8-76D4-45F3-936D-D8498CC9CC1C

P478

Q37381606-31D5F7D8-6A85-4E3C-9765-7AE31A621A33

P50

Q37381606-55698056-4940-4B8B-BA43-603D250F5236

Q37381606-9405595A-AF98-42B3-AC11-E16E8EB80F54

P577

Q37381606-932987D0-839D-4C23-BF18-E7100D139097

P5875

Q37381606-FB215DC0-9CA6-46AC-86DD-2E8B21D7D1BC

P698

Q37381606-D8050EDE-5EB5-4F53-8DE4-F71CD6D3C06C

P932

Q37381606-FCED796C-5461-4C69-96F2-ECBEB4D6BA70

P356

ONCOTARGET.1412

P1433

P1476

Efficient induction of differe ...... the DNMT Inhibitor Decitabine

@en

P2093

Agnes Viale

http://www.w3.org/2001/XMLSchema#string

Alexandra Borodovsky

http://www.w3.org/2001/XMLSchema#string

Alicia Pedraza

http://www.w3.org/2001/XMLSchema#string

Armida W M Fabius

http://www.w3.org/2001/XMLSchema#string

Gregory J Riggins

http://www.w3.org/2001/XMLSchema#string

Jason Huse

http://www.w3.org/2001/XMLSchema#string

Timothy A Chan

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

P304

1729-1736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1412

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Cameron Brennan

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257205553

http://www.w3.org/2001/XMLSchema#string

P698

24077826

http://www.w3.org/2001/XMLSchema#string

P932

3858559

http://www.w3.org/2001/XMLSchema#string